Natural history of hepatitis C

Journal of Hepatology

Volumn 61, Issue 1, 2014, Pages S58-S68

  Westbrook, Rachel H ^a   Dusheiko, Geoffrey ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Acute hepatitis C; Antiviral treatment; Chronic hepatitis C; Cirrhosis; Direct acting antivirals; Hepatocellular carcinoma.; Interferon; Liver transplantation; Natural history of hepatitis C

Indexed keywords

ACUTE DISEASE; CANCER RISK; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; HEPATITIS C; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION RISK; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MEN WHO HAVE SEX WITH MEN; PORTAL HYPERTENSION; QUALITY OF LIFE; REINFECTION; REVIEW; RISK ASSESSMENT; SEXUALLY TRANSMITTED DISEASE; THERAPY EFFECT; TREATMENT OUTCOME; CARCINOMA, HEPATOCELLULAR; COMPLICATION; LIVER NEOPLASMS; RISK FACTOR;

ANTIVIRUS AGENT;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; RISK FACTORS;

EID: 84913592791     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.07.012     Document Type: Review

References (92)

1. K. Mohd Hanafiah, J. Groeger, A.D. Flaxman, and S.T. Wiersma Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 57 2013 1333 1342
2. D. Lavanchy Evolving epidemiology of hepatitis C virus Clin Microbiol Infect 17 2011 107 115
3. T.J. van de Laar, G.V. Matthews, M. Prins, and M. Danta Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection AIDS 24 2010 1799 1812
4. J.F. Perz, G.L. Armstrong, L.A. Farrington, Y.J. Hutin, and B.P. Bell The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide J Hepatol 45 2006 529 538
5. L. Alric, M. Fort, J. Izopet, J.P. Vinel, J.P. Charlet, and J. Selves Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection Gastroenterology 113 1997 1675 1681
6. J. Grebely, K. Page, R. Sacks-Davis, M.S. van der Loeff, T.M. Rice, and J. Bruneau The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection Hepatology 59 2014 109 120
7. D.L. Thomas, C.L. Thio, M.P. Martin, Y. Qi, D. Ge, and C. O'Huigin Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
8. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
9. C.C. Wang, E. Krantz, J. Klarquist, M. Krows, L. McBride, and E.P. Scott Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance J Infect Dis 196 2007 1474 1482
10. L.T. Yeung, T. To, S.M. King, and E.A. Roberts Spontaneous clearance of childhood hepatitis C virus infection J Viral Hepat 14 2007 797 805
11. A.L. Cox, D.M. Netski, T. Mosbruger, S.G. Sherman, S. Strathdee, and D. Ompad Prospective evaluation of community-acquired acute-phase hepatitis C virus infection Clin Infect Dis 40 2005 951 958
12. S.M. Kamal, S.K. Kassim, A.I. Ahmed, S. Mahmoud, K.A. Bahnasy, and T.A. Hafez Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study Am J Gastroenterol 109 2014 199 211
13. W.O. Osburn, A.E. Snider, B.L. Wells, R. Latanich, J.R. Bailey, and D.L. Thomas Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses Hepatology 59 6 2014 2140 2151
14. P. Kokordelis, B. Kramer, C. Korner, C. Boesecke, E. Voigt, and P. Ingiliz An effective interferon-gamma-mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficiency virus-positive patients Hepatology 59 2014 814 827
15. G.H. Haydon, L.M. Jarvis, C.S. Blair, P. Simmonds, D.J. Harrison, and K.J. Simpson Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection Gut 42 1998 570 575
16. B.J. McMahon, D. Bruden, M.G. Bruce, S. Livingston, C. Christensen, and C. Homan Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection Gastroenterology 138 2010 e921
17. D.S. Fierer, D.T. Dieterich, M.P. Mullen, A.D. Branch, A.J. Uriel, and D.C. Carriero Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men Clin Infect Dis 58 2014 873 879
18. L.E. Taylor, J.A. Foont, A.K. DeLong, A. Wurcel, B.P. Linas, and S. Chapman The spectrum of undiagnosed hepatitis C virus infection in a US HIV clinic AIDS Patient Care STDS 28 2014 4 9
19. T. Abdelrahman, J. Hughes, J. Main, J. McLauchlan, M. Thursz, and E. Thomson Next generation sequencing sheds light on the natural history of hepatitis C infection in patients that fail treatment Hepatology 2014 [Epub ahead of print]
20. N.K. Martin, P. Vickerman, G.R. Foster, S.J. Hutchinson, D.J. Goldberg, and M. Hickman Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility J Hepatol 54 2011 1137 1144
21. F. Martin, T. Kiwanuka, R. Kawuma, F. Zalwango, and J. Seeley Tasks and strategies of self-management of living with antiretroviral therapy in Uganda AIDS Patient Care STDS 27 2013 697 706
22. M.J. Tong, N.S. el-Farra, A.R. Reikes, and R.L. Co Clinical outcomes after transfusion-associated hepatitis C N Engl J Med 332 1995 1463 1466
23. M. Wiese, F. Berr, M. Lafrenz, H. Porst, and U. Oesen Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study Hepatology 32 2000 91 96
24. M. Yano, H. Kumada, M. Kage, K. Ikeda, K. Shimamatsu, and O. Inoue The long-term pathological evolution of chronic hepatitis C Hepatology 23 1996 1334 1340
25. M. Kobayashi, E. Tanaka, T. Sodeyama, A. Urushihara, A. Matsumoto, and K. Kiyosawa The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses Hepatology 23 1996 695 699
26. E. Kenny-Walsh Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group N Engl J Med 340 1999 1228 1233
27. D.L. Thomas, J. Astemborski, R.M. Rai, F.A. Anania, M. Schaeffer, and N. Galai The natural history of hepatitis C virus infection: host, viral, and environmental factors JAMA 284 2000 450 456
28. H.H. Thein, Q. Yi, G.J. Dore, and M.D. Krahn Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression Hepatology 48 2008 418 431
29. H. Watanabe, T. Saito, H. Shinzawa, K. Okumoto, E. Hattori, and T. Adachi Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: a population-based cohort study J Med Virol 71 2003 56 61
30. S. Zeuzem Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 140 2004 370 381
31. C. Datz, M. Cramp, T. Haas, O. Dietze, H. Nitschko, and G. Froesner The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre Gut 44 1999 563 567
32. Q. Yi, P.P. Wang, and M. Krahn Improving the accuracy of long-term prognostic estimates in hepatitis C virus infection J Viral Hepat 11 2004 166 174
33. T. Poynard, V. Ratziu, Y. Benmanov, V. Di Martino, P. Bedossa, and P. Opolon Fibrosis in patients with chronic hepatitis C: detection and significance Semin Liver Dis 20 2000 47 55
34. T. Poynard, M.F. Yuen, V. Ratziu, and C.L. Lai Viral hepatitis C Lancet 362 2003 2095 2100
35. S. Deuffic-Burban, T. Poynard, and A.J. Valleron Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model J Viral Hepat 9 2002 114 122
36. L. Castera, C. Hezode, F. Roudot-Thoraval, A. Bastie, E.S. Zafrani, and J.M. Pawlotsky Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies Gut 52 2003 288 292
37. L.E. Adinolfi, M. Gambardella, A. Andreana, M.F. Tripodi, R. Utili, and G. Ruggiero Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity Hepatology 33 2001 1358 1364
38. H.H. Thein, Q. Yi, G.J. Dore, and M.D. Krahn Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis AIDS 22 2008 1979 1991
39. L. Martin-Carbonero, V. de Ledinghen, A. Moreno, I. Maida, J. Foucher, and P. Barreiro Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection J Viral Hepat 16 2009 790 795
40. A. Aghemo, and M. Colombo Treatment of patients with dual hepatitis B and C: a step in the right direction Gut 63 2014 380 381
41. L.Y. Cho, J.J. Yang, K.P. Ko, B. Park, A. Shin, and M.K. Lim Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis Int J Cancer 128 2011 176 184
42. G. Squadrito, T. Pollicino, I. Cacciola, G. Caccamo, D. Villari, and T. La Masa Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients Cancer 106 2006 1326 1330
43. P. Marcellin, N. Boyer, A. Gervais, M. Martinot, M. Pouteau, and C. Castelnau Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy Ann Intern Med 127 1997 875 881
44. T. Poynard, J. Moussalli, M. Munteanu, D. Thabut, P. Lebray, and M. Rudler Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C J Hepatol 59 2013 675 683
45. S. Maylin, M. Martinot-Peignoux, R. Moucari, N. Boyer, M.P. Ripault, and D. Cazals-Hatem Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C Gastroenterology 135 2008 821 829
46. F. Toccaceli, V. Laghi, L. Capurso, M. Koch, S. Sereno, and M. Scuderi Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon J Viral Hepat 10 2003 126 133
47. T. Poynard, J. McHutchison, M. Manns, C. Trepo, K. Lindsay, and Z. Goodman Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313
48. Y. Shiratori, F. Imazeki, M. Moriyama, M. Yano, Y. Arakawa, and O. Yokosuka Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy Ann Intern Med 132 2000 517 524
49. L.I. Backus, D.B. Boothroyd, B.R. Phillips, P. Belperio, J. Halloran, and L.A. Mole A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C Clin Gastroenterol Hepatol 9 2011 e501
50. R.J. Fontana, A.J. Sanyal, M.G. Ghany, W.M. Lee, A.E. Reid, and D. Naishadham Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C Gastroenterology 138 2010 2321 2331 2331.e2321-e2322
51. A. Sangiovanni, G.M. Prati, P. Fasani, G. Ronchi, R. Romeo, and M. Manini The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients Hepatology 43 2006 1303 1310
52. L. Benvegnu, M. Gios, S. Boccato, and A. Alberti Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications Gut 53 2004 744 749
53. R.J. Fontana, A.J. Sanyal, M.G. Ghany, H.L. Bonkovsky, T.R. Morgan, and H.J. Litman Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C Am J Gastroenterol 106 2011 884 893
54. D. Rincon, C. Ripoll, O. Lo Iacono, M. Salcedo, M.V. Catalina, and E. Alvarez Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis Am J Gastroenterol 101 2006 2269 2274
55. S. Bruno, A. Crosignani, C. Facciotto, S. Rossi, L. Roffi, and A. Redaelli Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study Hepatology 51 2010 2069 2076
56. B. Goodgame, N.J. Shaheen, J. Galanko, and H.B. El-Serag The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol 98 2003 2535 2542
57. H.B. El-Serag, A.B. Siegel, J.A. Davila, Y.H. Shaib, M. Cayton-Woody, and R. McBride Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study J Hepatol 44 2006 158 166
58. C.H. Hung, C.M. Lee, S.N. Lu, J.H. Wang, T.H. Hu, and H.D. Tung Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis J Viral Hepat 13 2006 409 414
59. K. Ikeda, S. Saitoh, Y. Arase, K. Chayama, Y. Suzuki, and M. Kobayashi Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis Hepatology 29 1999 1124 1130
60. R.L. Morgan, B. Baack, B.D. Smith, A. Yartel, M. Pitasi, and Y. Falck-Ytter Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies Ann Intern Med 158 2013 329 337
61. T.R. Morgan, M.G. Ghany, H.Y. Kim, K.K. Snow, M.L. Shiffman, and J.L. De Santo Outcome of sustained virological responders with histologically advanced chronic hepatitis C Hepatology 52 2010 833 844
62. T. Thevenot, C. Regimbeau, V. Ratziu, V. Leroy, P. Opolon, and T. Poynard Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update J Viral Hepat 8 2001 48 62
63. S. Aleman, N. Rahbin, O. Weiland, L. Davidsdottir, M. Hedenstierna, and N. Rose A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis Clin Infect Dis 57 2013 230 236
64. K.C. Chang, C.H. Hung, S.N. Lu, J.H. Wang, C.M. Lee, and C.H. Chen A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy J Antimicrob Chemother 67 2012 2766 2772
65. G.T. Everson, J. Trotter, L. Forman, M. Kugelmas, A. Halprin, and B. Fey Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy Hepatology 42 2005 255 262
66. L.M. Forman, J.D. Lewis, J.A. Berlin, H.I. Feldman, and M.R. Lucey The association between hepatitis C infection and survival after orthotopic liver transplantation Gastroenterology 122 2002 889 896
67. M. Garcia-Retortillo, X. Forns, A. Feliu, E. Moitinho, J. Costa, and M. Navasa Hepatitis C virus kinetics during and immediately after liver transplantation Hepatology 35 2002 680 687
68. N. Yilmaz, M.L. Shiffman, R.T. Stravitz, R.K. Sterling, V.A. Luketic, and A.J. Sanyal A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation Liver Transpl 13 2007 975 983
69. A. Sanchez-Fueyo, J.C. Restrepo, L. Quinto, M. Bruguera, L. Grande, and J.M. Sanchez-Tapias Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft Transplantation 73 2002 56 63
70. E.J. Gane, B.C. Portmann, N.V. Naoumov, H.M. Smith, J.A. Underhill, and P.T. Donaldson Long-term outcome of hepatitis C infection after liver transplantation N Engl J Med 334 1996 815 820
71. U.P. Neumann, T. Berg, M. Bahra, D. Seehofer, J.M. Langrehr, and R. Neuhaus Fibrosis progression after liver transplantation in patients with recurrent hepatitis C J Hepatol 41 2004 830 836
72. T.K. Narang, W. Ahrens, and M.W. Russo Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria Liver Transpl 16 2010 1228 1235
73. I.A. Rowe, K. Webb, B.K. Gunson, N. Mehta, S. Haque, and J. Neuberger The impact of disease recurrence on graft survival following liver transplantation: a single centre experience Transpl Int 21 2008 459 465
74. M. Berenguer, M. Prieto, F. San Juan, J.M. Rayon, F. Martinez, and D. Carrasco Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients Hepatology 36 2002 202 210
75. D.N. Samonakis, G. Germani, and A.K. Burroughs Immunosuppression and HCV recurrence after liver transplantation J Hepatol 56 2012 973 983
76. N. Terrault, K.R. Reddy, F. Poordad, M. Curry, T. Schiano, and J. Johl Peginterferon and ribavirin for treatment of recurrent hepatitis C disease in HCV-HIV coinfected liver transplant recipients Am J Transplant 14 2014 1129 1135
77. N.A. Terrault, M.L. Shiffman, A.S. Lok, S. Saab, L. Tong, and R.S. Brown Jr. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation Liver Transpl 13 2007 122 129
78. R.T. Stravitz, M.L. Shiffman, A.J. Sanyal, V.A. Luketic, R.K. Sterling, and D.M. Heuman Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation Liver Transpl 10 2004 850 858
79. L.E. Adinolfi, L. Restivo, B. Guerrera, A. Sellitto, A. Ciervo, and N. Iuliano Chronic HCV infection is a risk factor of ischemic stroke Atherosclerosis 231 2013 22 26
80. A.L. Mason, J.Y. Lau, N. Hoang, K. Qian, G.J. Alexander, and L. Xu Association of diabetes mellitus and chronic hepatitis C virus infection Hepatology 29 1999 328 333
81. Y.C. Hsu, J.T. Lin, H.J. Ho, Y.H. Kao, Y.T. Huang, and N.W. Hsiao Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients Hepatology 59 2014 1293 1302
82. Y. Arase, F. Suzuki, Y. Suzuki, N. Akuta, M. Kobayashi, and Y. Kawamura Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C Hepatology 49 2009 739 744
83. E.A. Akriviadis, I. Xanthakis, C. Navrozidou, and A. Papadopoulos Prevalence of cryoglobulinemia in chronic hepatitis C virus infection and response to treatment with interferon-alpha J Clin Gastroenterol 25 1997 612 618
84. N. Merchante, E. Merino, F. Rodriguez-Arrondo, C. Tural, J. Munoz, and M. Delgado-Fernandez HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma AIDS 28 2014 41 47
85. D. Salmon-Ceron, E. Rosenthal, C. Lewden, V. Bouteloup, T. May, and C. Burty Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalite 2005 study J Hepatol 50 2009 736 745
86. G.N. Ioannou, C.L. Bryson, N.S. Weiss, R. Miller, J.D. Scott, and E.J. Boyko The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection Hepatology 57 2013 249 257
87. G.R. Foster Quality of life considerations for patients with chronic hepatitis C J Viral Hepat 16 2009 605 611
88. D. Yamini, B. Basseri, G.M. Chee, A. Arakelyan, P. Enayati, and T.T. Tran Tobacco and other factors have a negative impact on quality of life in hepatitis C patients J Viral Hepat 18 2011 714 720
89. C.M. Hunt, J.A. Dominitz, B.P. Bute, B. Waters, U. Blasi, and D.M. Williams Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life Dig Dis Sci 42 1997 2482 2486
90. H.L. Bonkovsky, and J.M. Woolley Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group Hepatology 29 1999 264 270
91. N.K. Martin, P. Vickerman, A. Miners, G.R. Foster, S.J. Hutchinson, and D.J. Goldberg Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations Hepatology 55 2012 49 57
92. H. Innes, D. Goldberg, G. Dusheiko, P. Hayes, P.R. Mills, and J.F. Dillon Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model J Hepatol 60 2014 1118 1126